



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/806852
				Filing Date	March 23, 2004
				First Named Inventor	David C. Rueger
				Art Unit	1653
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	JJJ-P02-511

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
CYW	BG	WO 92/00382	01-09-1992	Carnegie Institution of Washington		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	CN1	JONES, et al. "Involvement of Bone Morphogenetic Protein 4 (BMP 4) and Vgr 1 in morphogenesis and neurogenesis in the mouse", Development 111, 531-542 (1991).			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Chang-Yu Wang/	Date Considered	01/11/2007
-----------------------	-----------------	--------------------	------------



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
				Application Number	10/806852
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Filing Date	March 23, 2004
				First Named Inventor	David Rueger
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	JJJ-P02-511
Sheet	1	of	3		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA**	US-5,108,989	04-28-1992	AMENTO et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
CYW	BA**	WO 84/01106	03-29-1984			
	BB**	WO 92/15323	09-17-1992			
	BC**	WO 94/03200	02-17-1994			
	BD**	WO 95/05846	03-02-1995			
	BE**	WO 95/06656	03-09-1995			
CYW	BF**	WO 95/10611	04-20-1995			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with a double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
CYW	CA**	AEBISCHER, et al. (1989), "Basic Fibroblast Growth Factor Released From Synthetic Guidance Channels Facilitating Peripheral Nerve Regeneration Across Long Nerve Gaps," 23 J. Neurosci. Res. 282-289.		
V	CB**	BARDE (1989), "Trophic Factors and Neuronal Survival," 2 Neuron 1525-1534.		
	CC**	BASLER, et al., (1993), "Control of Cell Pattern in the Neural Tube: Regulation of Cell Differentiation by dorsalin-1, a Novel TGFB Family Member", 73 Cell, 687-702.		
	CD**	CARSWELL (1993), "The Potential for Treating Neurodegenerative Disorders with NGF-Inducing Compounds," 124 Exp. Neurol. 36.		
	CE**	DE KONINCK, et al. (1993), "NGF Induced Neonatal Rat Sensory Neurons to Extend Dendrites in Culture After Removal of Satellite Cells," 13 J. Neurosci. 577-585.		
	CF**	DEININGER, et al. (1995), "Detection of Two Transforming Growth Factor-B-Related Morphogens, Bone Morphogenetic Proteins -4 and 05, in RNA of Multiple Sclerosis and creutzfeldt-Jakob Disease Lesions," 90 Acta Neuropathol. 76-79.		
	CG**	DEDHAR, et al., (1993), "Differential Regulation of Expression of Specific Integrin Receptors by Nerve Growth Factor and Transforming Growth Factor B1 During Differentiation of Human Neuroblastoma Cells", 1(1): Molecular and Cellular Differentiation, 1-20.		
	CH**	EBENDAL (1992), "Function and Evolution in the NGF Family and Its Receptors," 32 J. Neurosci. Res. 461.		
C	CI**	EBENDAL, et al. (1991) "Human Nerve Growth Factor: Biological and Immunological Activities, and Clinical Possibilities in the Neurodegenerative Disease," Plasticity and Regeneration of the Nervous System 207-225 (Timeras, et al., eds. Plenum Press NY).		
	CJ**	FRIEDLANDER, et al. (1986), "Nerve Growth Factor Enhances Expression of Neuron-Bla Cell		

Examiner Signature	/Chang-Yu Wang/	Date Considered	01/11/2007
--------------------	-----------------	-----------------	------------

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
		Application Number	10/806852		
		Filing Date	March 23, 2004		
		First Named Inventor	David Rueger		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
		Attorney Docket Number	JJJ-P02-511		
Sheet	2	of	3		

		Adhesion Molecule in PC12 Cells," 102 J.C.B. 413-419.	
CYW	CK**	GASH, et al. (1996), "Functional Recovery in Parkinsonian Monkeys Treated with GDNF," 380 Nature 252-255.	
	CL**	GROSS, et al. (1993), "Transforming Growth Factor-B1 Reduces Infarct Size After Experimental Cerebral Ischemia in a Rabbit Model," 24 Stroke 558-562.	
	CM**	HEFTI, et al. (1993), "Pharmacology of Nerve Growth Factor in the Brain," 24 Adv. in Pharmacol. 239-273.	
	CN**	JACKOWSKI, et al. (1995), "Neural Injury Repair: Hope For The Future As Barrier To Effective CNS Regeneration Become Clearer," 9 Brit. J. Neurosurgery, 303-317.	
	CO**	Jones, et al. (1991), "Involvement of Bone Morphogenetic Proteins..." 111 Development 2:531-542.	
	CP**	LEE (1991), "Expression of Growth/Differentiation Factor 1 in the Nervous System: Conservation of a Bicistronic Structure," 88 Proc. Natl. Acad. Sci USA, 4250-4254.	
	CQ**	LEFER, et al (1992), "Anti-Ischaemic and Endothelial Protective Actions of Recombinant Human Osteogenic Protein (hOP-1)," J. Mol. Cell. Card 24:585-593.	
	CR**	LEIN, et al. (1995), "Osteogenic Protein-1 Induces Dendritic Growth in Rat Sympathetic Neurons in Vitro," 15 Neuron 597-605.	
	CS**	LEIN, et al. (1989), "Laminin and a Basement Membrane Extract Have Different Effects on Axonal and Dendritic Outgrowth From Embryonic Rat Sympathetic Neurons in Vitro," 136 Dev. Biol. 330-345.	
	CT**	LEROUX, et al (1994), "Regional Differences in Glial-Derived Factors That Promote Dendritic Outgrowth From Mouse Cortical Neurons In Vitro," 14 J. Neurosci. 8:4639-4655.	
	CU**	LUNDBORG (1987), "Nerve Regeneration and Repair," 58 Acta. Orthop. Scand. 145-169.	
	CV**	PERIDES, et al. (1995), "Neuroprotective Effect of Human Osteogenic Protein 1 in a Rat Model of Cerebral Hypoxia/Ischemia," 187 Neurosci. Lett. 21-24.	
	CW**	PURVES, et al. (1988), "Trophic Regulation of Nerve Cell Morphology and Innervation in the Autonomic Nervous System," 336 Nature 123-128.	
	CX**	REISSMAN, et al. (1996), "Involvement of Bone Morphogenetic Protein-4 and Bone Morphogenetic Protein-7 In The Differentiation of the Adrenergic Phenotype In Developing Sympathetic Neurons," 122 Development 2079-2088.	
	CY**	ROUBIN, et al (1990), "Modulation of NCAM Expression by Transforming Growth Factor-Beta, Serum, and Autocrine Factors," 111 J. Cell Biol. 673-684.	
	CZ**	SADD, et al. (1991), "Astrocyte-Derived TGF-B2 and NGF Differentially Regulate Neural Recognition Molecule Expression by Cultured Astrocytes," J. Cell Biol. 2473-483.	
	CA1**	SASAI, et al. (1995), "Regulation of Neural Induction by the Chd and Bmp-4 Antagonistic Patterning Signals in Xenopus," Nature 367:333-356.	
	CB1**	SCHUBERT, et al., (1990) "Activin is a Nerve Cell Survival Molecule", Nature, 344:868:870.	
	CC1**	SHAH, et al. (1995), "Alternative Neural Crest Cell Fates Are Instructively Promoted by TGF-B Superfamily Members," 85 Cell 331-343.	
	CD1**	SNIDER (1988), "Nerve Growth Factor Enhances Dendritic Arborization of Sympathetic Ganglion Cells in Developing Mammals," 8 J. Neurosci. 2628-2634.	
	CE1**	Stromberg, et al. (1993), "Glial Cell Line-Derived Neurotrophic Factor is Expressed in the Developing but Not Adult Striatum and Stimulates Developing Dopamine Neurons in vivo," 124 Exp. Neurol. 401-412.	
	CF1**	TOMAC, et al. (1995), "Protection and Repair of the Nigrostriatal Dopaminergic System by GDNF in vivo," 373 Nature 335-346.	
	CG1**	WILSON, et al. (1995), "Induction of Epidermis and Inhibition of Neural Fate by Bmp-4," 376 Nature 331-333.	
CYW	CH1**	WITHERS, et al. (1996), "Receptivity of Osteogenic Protein-1 (P-1) - Induced Dendrites to Axonal Innervation," Society for Neuroscience, meeting abstract.	

Examiner Signature	/Chang-Yu Wang/	Date Considered	01/11/2007
--------------------	-----------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/806852
				Filing Date	March 23, 2004
				First Named Inventor	David Rueger
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	JJJ-P02-511

CYW	CI1**	WITHERS, et al. (1995), "Osteogenic Protein-1 (OP-1) Induces Dendritic Growth and Branching in Cultured Hippocampal Neurons", Society for Neuroscience, meeting abstract.	
	CJ1**	RUDINGER, (1976), Peptide Hormones, ed. Parsons, Univ. Park Press, p. 1-7.	
↓	CK1**	VARLEY, et al., (1995) Developmental Dynamics 203:434-447.	
	CL1**	The Merck Manual of Diagnosis and Therapy, 16th ed., (editor-in-chief Berkow), p. 1512-1513.	
CYW	CM1*	GUO, et al. (1998), "Osteogenic protein-1 and related bone morphogenetic proteins regulate dendritic growth and the expression of microtubule-associated protein-2 in rat sympathetic neurons," Neuroscience Letters 245 131-134.	

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Chang-Yu Wang/	Date Considered	01/11/2007
-----------------------	-----------------	--------------------	------------